Authors
Latest:
Immune Modulation in Sarcoma: Targeting the Tumor MicroenvironmentExplore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.
Latest:
CDK4/6 Inhibitor Use May Expand in HR+ HER2– Breast CancerDaniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Latest:
Bispecifics in R/R MM: Unanswered QuestionsPanelists discuss how despite the significant progress with bispecifics in relapsed/refractory multiple myeloma (R/R MM), major unanswered questions remain including optimal sequencing strategies (which represent the biggest challenge), how to implement bispecifics earlier in the treatment paradigm, and how to integrate them with other existing therapies in the evolving treatment landscape.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
ABBV-400 Shows Early Promise in Pretreated, Metastatic Colorectal Cancer“It does appear like MET expression could be one of the mechanisms wherein you could differentiate between responders and non-responders,” Kanwal P.S. Raghav, MBBS, MD, stated.
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
Latest:
Precision Medicine in NSCLC The Power of Molecular TestingPersonalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.
Latest:
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.
Latest:
Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardFinal remarks and presentation of awards.
Latest:
Product Profile of Amivantamab Plus Chemotherapy in EGFR Exon 20+ NSCLCTammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
